NCT06160362View on ClinicalTrials.gov

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-hodgkin Lymphoma,B Cell
Interventions
BIOLOGICAL

CART-19 and 20 cells

Double-target CART-19 and 20 cells will be administered on day0 after completion of the chemotherapy.

DRUG

Cyclophosphamide

patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).

DRUG

Fludarabine

Fludarabine 25mg/m2/day IV for 3 days (Day-4 to day-2).

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV